Françoise Rothé

List of Publications by Year
in descending order

23 papers	2,698 citations	20 h-index (361413)
23 g-index (642732)	24 all docs	24 docs citations
24 times ranked	5830 citing authors	

#	Article	IF	Citations
1	CD4+ follicular helper T cell infiltration predicts breast cancer survival. Journal of Clinical Investigation, 2013, 123, 2873-2892.	8.2	813
2	Human natural Treg microRNA signature: Role of microRNAâ€31 and microRNAâ€21 in FOXP3 expression. European Journal of Immunology, 2009, 39, 1608-1618.	2.9	252
3	Genomic Characterization of Primary Invasive Lobular Breast Cancer. Journal of Clinical Oncology, 2016, 34, 1872-1881.	1.6	249
4	Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer. PLoS ONE, 2011, 6, e20980.	2.5	214
5	DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Molecular Medicine, 2011, 3, 726-741.	6.9	210
6	HER2-Positive Circulating Tumor Cells in Breast Cancer. PLoS ONE, 2011, 6, e15624.	2.5	176
7	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy. JAMA Oncology, 2017, 3, 227.	7.1	118
8	Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer. Modern Pathology, 2017, 30, 1204-1212.	5.5	81
9	Immune Infiltration in Invasive Lobular Breast Cancer. Journal of the National Cancer Institute, 2018, 110, 768-776.	6.3	76
10	Uncovering the genomic heterogeneity of multifocal breast cancer. Journal of Pathology, 2015, 236, 457-466.	4.5	72
11	Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer. Gut, 2016, 65, 990-1000.	12.1	67
12	<scp>CDK</scp>4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib. EMBO Molecular Medicine, 2017, 9, 1052-1066.	6.9	65
13	Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy. Journal of the National Cancer Institute, 2019, 111, 69-77.	6.3	60
14	Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology. BMC Genomics, 2014, 15, 1008.	2.8	52
15	International study on inter-reader variability for circulating tumor cells in breast cancer. Breast Cancer Research, 2014, 16, R43.	5.0	43
16	Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial. Breast, 2013, 22, 1060-1065.	2.2	33
17	Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors. Nature Cancer, 2021, 2, 611-628.	13.2	30
18	ESR1 mutations in metastatic lobular breast cancer patients. Npj Breast Cancer, 2019, 5, 9.	5.2	26

#	Article	IF	Citations
19	Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer. Breast Cancer Research, 2019, 21, 25.	5.0	22
20	Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer. Clinical Cancer Research, 2020, 26, 6254-6265.	7.0	22
21	Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis. Npj Breast Cancer, 2022, 8, .	5.2	8
22	Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. Clinical Cancer Research, 2021, 27, 5607-5618.	7.0	5
23	Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays. PLoS ONE, 2018, 13, e0203346.	2.5	4